Mundipharma and Northlake International have joined forces to develop structurally new next generation alkylating agents to treat haematological malignancies.
Under the $84.5m agreement, Mundipharma and its independent associated companies across the globe will acquire intellectual property rights, excluding China, of Northlake International's lead product NL-101 as well as its pipeline of back-up molecules.
Mundipharma Research director Karen Reimer said NL-101 in cell lines has shown five times higher DNA alkylation efficiency than melphalan and is ten times more potent than bendamustine.
"Mundipharma's agreement with Northlake International is yet another example of our heritage of partnering and co-developing with companies," Reimer added.
Northlake International CSO and co-founder Yi Chen said, "This collaboration leverages Mundipharma's expertise with bendamustine along with our DCTT technology and will help bring important new therapies to patients and physicians."
In addition to Northlake collaboaration, Mundipharma has also signed a Data Sharing Agreement with Hangzhou Minsheng Pharmaceutical, which owns the Chinese rights for NL-101.
NL-101is a fusion molecule that has bendamustine back-bone plus a histone deacetylase pharmacophore and is developed through Northlake International's Dual Functional Cytotoxic Targeted Therapy (DCTT) technology.
